GO:1903543 positive regulation of exosomal secretion: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903543 describes any process that increases the frequency, rate, or extent of exosomal secretion, a key intercellular communication mechanism.
• Exosomal secretion is positively regulated by diverse stimuli including TNF-alpha, IL-6, and oncogenic signals, often through Rab GTPases and ESCRT machinery [2,6,5].
• Tumor-derived exosomes carrying miR-934, circCCAR1, or PD-1 can reprogram macrophages, impair T cells, and promote immune evasion [1,3,8].
• Exosomal cargo such as miR-138-5p and LCN2 modulates macrophage polarization and tissue degeneration, linking this process to inflammation and fibrosis [4,7].
• GP73-dependent regulation of exosome biogenesis promotes colorectal cancer liver metastasis, highlighting therapeutic potential.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect causal roles of genes in exosomal secretion.
Description
Exosomes are small extracellular vesicles of endosomal origin that mediate intercellular communication by transferring proteins, lipids, and nucleic acids. The process of exosomal secretion is tightly regulated, and its positive regulation is annotated under the Gene Ontology term GO:1903543, defined as any process that activates or increases the frequency, rate, or extent of exosomal secretion. This term encompasses signaling events that stimulate the biogenesis, trafficking, and release of exosomes from cells [2,6]. Understanding positive regulation of exosomal secretion is critical because dysregulated exosome release contributes to cancer progression, immune modulation, and metabolic diseases. For example, TNF-alpha-treated mesenchymal stem cells enhance exosome secretion, which promotes M2 macrophage polarization and inhibits periodontal bone loss. Similarly, myeloid cell-specific IL-6 signaling increases microRNA-223-enriched exosome production to attenuate NAFLD-associated fibrosis. These findings underscore the importance of identifying the molecular players that upregulate exosomal secretion. In cancer, tumor-derived exosomes carrying miR-934 induce macrophage M2 polarization to promote liver metastasis of colorectal cancer. Exosome-derived circCCAR1 from hepatocellular carcinoma promotes CD8+ T-cell dysfunction and anti-PD1 resistance. Prostate cancer cells secrete PD-1 in exosomes to enhance myeloid-derived suppressor cell activity and promote immune evasion. Thus, positive regulation of exosomal secretion is a double-edged sword: beneficial in tissue repair and metabolic homeostasis, but detrimental in cancer and chronic inflammation. Researchers studying this process need robust tools to manipulate and measure exosomal secretion. This article integrates authoritative GO annotation with real PubMed literature to provide a comprehensive overview of the mechanisms, key genes, diseases, and research methods associated with GO:1903543.
positive regulation of exosomal secretion At A Glance
| GO ID | GO:1903543 |
|---|---|
| GO term | positive regulation of exosomal secretion |
| Ontology | biological_process |
| Synonym | activation of exosomal secretion; upregulation of exosomal secretion; positive regulation of exosomal secretory pathway; activation of extracellular vesicular exosome secretion |
| Major function | Increases the frequency, rate, or extent of exosome release from cells |
| Related terms | regulation of exosomal secretion (GO:1903542); negative regulation of exosomal secretion (GO:1903544); exosomal secretion (GO:1990182) |
| Found in | Various cell types including cancer cells, immune cells, mesenchymal stem cells, and hepatocytes |
| Key regulators | Rab GTPases, ESCRT components, sphingomyelinase, IL-6/STAT3, TNF-alpha/NF-kB signaling |
What Is GO:1903543?
GO:1903543, positive regulation of exosomal secretion, is a biological process term that describes any mechanism that activates or increases the frequency, rate, or extent of exosomal secretion. Exosomal secretion is the process by which exosomes, a subtype of extracellular vesicles, are released from cells. This regulation can occur at multiple steps, including exosome biogenesis, cargo sorting, trafficking to the plasma membrane, and membrane fusion. The term is a child of positive regulation of secretion and regulation of exosomal secretion, and it specifically covers upregulatory events, as opposed to negative regulation (GO:1903544).
Why Is positive regulation of exosomal secretion Important in Cell Biology?
Positive regulation of exosomal secretion is critically important because exosomes mediate intercellular communication in both physiological and pathological contexts. Upregulated exosome release can amplify immune responses, promote tissue repair, or drive disease progression. In cancer, tumor-derived exosomes can educate immune cells to support tumor growth and metastasis, as shown by miR-934-induced M2 macrophage polarization in colorectal cancer liver metastasis. In metabolic diseases, IL-6 signaling enhances exosome production to attenuate fibrosis, demonstrating a protective role. Therefore, understanding how this process is regulated offers opportunities for therapeutic intervention in cancer, inflammatory diseases, and metabolic disorders.
• Exosomes transfer bioactive molecules (miRNAs, circRNAs, proteins) that reprogram recipient cells, influencing tumor microenvironment and immune evasion [1,3,8].
• Positive regulation of exosomal secretion by TNF-alpha in mesenchymal stem cells enhances M2 macrophage polarization and reduces periodontal bone loss.
• IL-6 signaling promotes miR-223-enriched exosome production, which attenuates NAFLD-associated fibrosis.
• Cancer-derived exosomal miR-138-5p modulates macrophage polarization via KDM6B inhibition, affecting tumor progression.
• GP73-dependent regulation of exosome biogenesis promotes colorectal cancer liver metastasis, identifying a potential therapeutic target.
• M1 macrophage-derived exosomes enhance nucleus pulposus cell senescence through LCN2/NF-kB signaling, contributing to intervertebral disc degeneration.
• Prostate cancer cells secrete PD-1 in exosomes to enhance myeloid-derived suppressor cell activity, promoting immune evasion.
• Exosomal secretion is a key mechanism in intercellular communication, with roles in development, immunity, and tissue homeostasis.
• Dysregulation of exosomal secretion is implicated in cancer, fibrosis, neurodegeneration, and inflammatory diseases.
• Targeting positive regulators of exosomal secretion could lead to novel diagnostics and therapeutics.
What Happens During positive regulation of exosomal secretion?
Initiation of Exosome Biogenesis
In simple terms: Cells start making exosomes inside them when certain signals tell them to.
Positive regulation of exosomal secretion often begins with increased biogenesis of intraluminal vesicles (ILVs) within multivesicular bodies (MVBs). This step is stimulated by signaling pathways such as TNF-alpha/NF-kB and IL-6/STAT3. For instance, TNF-alpha treatment of gingiva-derived mesenchymal stem cells enhances exosome secretion, which promotes M2 macrophage polarization. Similarly, myeloid cell-specific IL-6 signaling increases the production of miR-223-enriched exosomes. The ESCRT machinery and accessory proteins like GP73 are involved in ILV formation; GP73-dependent regulation of exosome biogenesis promotes colorectal cancer liver metastasis.
Cargo Sorting and MVB Maturation
In simple terms: Specific molecules are packed into exosomes, and the container matures.
During positive regulation, specific cargoes such as microRNAs, circular RNAs, and proteins are selectively sorted into ILVs. For example, tumor-derived exosomal miR-934 is sorted into exosomes and induces macrophage M2 polarization to promote liver metastasis. Exosome-derived circCCAR1 is packaged and promotes CD8+ T-cell dysfunction in hepatocellular carcinoma. Prostate cancer cells sort PD-1 into exosomes to enhance myeloid-derived suppressor cell activity. This sorting is regulated by RNA-binding proteins and membrane microdomains, and is enhanced by positive regulatory signals.
MVB Trafficking to the Plasma Membrane
In simple terms: The container carrying exosomes moves to the cell surface.
MVBs must be transported along cytoskeletal tracks to the plasma membrane. Rab GTPases, particularly Rab27a and Rab27b, are key regulators of this trafficking step. Positive regulation of exosomal secretion often involves upregulation or activation of these Rab proteins. For instance, cancer-derived exosomal miR-138-5p modulates macrophage polarization, and its secretion is likely dependent on Rab-mediated trafficking. M1 macrophage-derived exosomes require efficient trafficking to promote intervertebral disc degeneration via LCN2/NF-kB signaling.
Membrane Fusion and Exosome Release
In simple terms: The container fuses with the cell membrane and releases exosomes outside.
The final step is the fusion of MVBs with the plasma membrane, releasing exosomes into the extracellular space. This step is mediated by SNARE proteins and is enhanced by positive regulatory signals. For example, GP73-dependent regulation promotes exosome biogenesis and release, facilitating colorectal cancer liver metastasis. IL-6 signaling increases exosome production, which attenuates NAFLD-associated fibrosis. TNF-alpha-treated mesenchymal stem cells release exosomes that inhibit periodontal bone loss.
Feedback and Amplification
In simple terms: The process can feed back to make even more exosomes.
Positive regulation can be amplified through feedback loops. For instance, exosomal miR-934 from colorectal cancer cells induces M2 macrophage polarization, which in turn may promote further exosome secretion, creating a pro-metastatic niche. Similarly, exosome-derived circCCAR1 promotes CD8+ T-cell dysfunction, potentially altering the immune microenvironment to sustain exosome release. Understanding these feedback mechanisms is crucial for therapeutic targeting.
Key Genes Involved in GO:1903543 positive regulation of exosomal secretion
The following genes and proteins have been experimentally implicated in the positive regulation of exosomal secretion, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| miR-934 | microRNA cargo in exosomes | Induces macrophage M2 polarization to promote colorectal cancer liver metastasis |
| TNF-alpha | Cytokine that stimulates exosome secretion | Enhances exosome release from gingiva-derived MSCs to inhibit periodontal bone loss |
| circCCAR1 | Circular RNA cargo in exosomes | Promotes CD8+ T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma |
| miR-138-5p | microRNA cargo in exosomes | Modulates tumor-associated macrophage polarization via KDM6B inhibition |
| GP73 | Golgi protein involved in exosome biogenesis | Regulates exosome biogenesis to promote colorectal cancer liver metastasis |
| IL-6 | Cytokine that promotes exosome production | Myeloid cell-specific IL-6 signaling increases miR-223-enriched exosome production to attenuate NAFLD fibrosis |
| LCN2 | Lipocalin-2, cargo in exosomes | M1 macrophage-derived exosomes enhance nucleus pulposus cell senescence via LCN2/NF-kB |
| PD-1 | Immune checkpoint protein secreted in exosomes | Prostate cancer cells secrete PD-1 in exosomes to enhance MDSC activity and immune evasion |
| Rab27a | GTPase regulating MVB trafficking | Key regulator of exosome secretion; often upregulated in positive regulation (implied by general knowledge, but not directly cited in provided list; omit specific citation) |
| Rab27b | GTPase regulating MVB trafficking | Similar to Rab27a; involved in exosome release (general knowledge, no specific citation from list) |
| ESCRT components | Protein complexes for ILV formation | Essential for exosome biogenesis; GP73 may interact with ESCRT |
| Sphingomyelinase | Enzyme producing ceramide for ILV formation | Ceramide promotes exosome biogenesis (general knowledge, no specific citation) |
| STAT3 | Transcription factor downstream of IL-6 | Mediates IL-6-induced exosome production |
| NF-kB | Transcription factor downstream of TNF-alpha | Mediates TNF-alpha-induced exosome secretion |
| KDM6B | Histone demethylase | Inhibited by miR-138-5p to modulate macrophage polarization |
| CD8+ T cells | Immune cells affected by exosomes | Exosomal circCCAR1 promotes their dysfunction |
| MDSCs | Myeloid-derived suppressor cells | Enhanced by exosomal PD-1 from prostate cancer |
How Is positive regulation of exosomal secretion Regulated?
Positive regulation of exosomal secretion is controlled by diverse signaling pathways. Inflammatory cytokines such as TNF-alpha and IL-6 stimulate exosome production through NF-kB and STAT3 signaling, respectively [2,6]. Oncogenic pathways can also upregulate exosome secretion; for example, GP73-dependent regulation promotes exosome biogenesis in colorectal cancer. Additionally, microRNAs and circular RNAs can act as cargo or regulators, influencing the secretion process and recipient cell responses [1,3,4]. The Rab GTPase family, particularly Rab27a/b, plays a central role in MVB trafficking and fusion, and their activity is often enhanced during positive regulation. However, specific regulatory mechanisms may vary by cell type and context.
positive regulation of exosomal secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| miR-934 | Colorectal cancer liver metastasis | Knockout of miR-934 in colorectal cancer cells; exosome isolation and macrophage polarization assays |
| circCCAR1 | Hepatocellular carcinoma, anti-PD1 resistance | Knockdown or overexpression of circCCAR1 in HCC cells; T-cell dysfunction assays |
| GP73 | Colorectal cancer liver metastasis | GP73 knockout in colorectal cancer cells; exosome biogenesis and metastasis models |
| IL-6 | NAFLD-associated fibrosis | Myeloid-specific IL-6 knockout mice; exosome production and fibrosis assessment |
| LCN2 | Intervertebral disc degeneration | LCN2 knockout or overexpression in macrophages; nucleus pulposus cell senescence assays |
Cancer Progression and Metastasis
Positive regulation of exosomal secretion is a hallmark of many cancers. Tumor-derived exosomes carrying miR-934 induce macrophage M2 polarization to promote liver metastasis of colorectal cancer. Exosome-derived circCCAR1 from hepatocellular carcinoma promotes CD8+ T-cell dysfunction and anti-PD1 resistance. Prostate cancer cells secrete PD-1 in exosomes to enhance myeloid-derived suppressor cell activity and promote immune evasion. GP73-dependent regulation of exosome biogenesis promotes colorectal cancer liver metastasis. These findings demonstrate that upregulated exosome secretion contributes to immune suppression, metastasis, and therapy resistance.
Inflammatory and Metabolic Diseases
Exosomal secretion is also important in inflammatory and metabolic conditions. TNF-alpha-treated gingiva-derived mesenchymal stem cells enhance exosome secretion, which promotes M2 macrophage polarization and inhibits periodontal bone loss. Myeloid cell-specific IL-6 signaling increases microRNA-223-enriched exosome production to attenuate NAFLD-associated fibrosis. M1 macrophage-derived exosomes promote intervertebral disc degeneration by enhancing nucleus pulposus cell senescence through LCN2/NF-kB signaling. Thus, positive regulation of exosomal secretion can have both protective and detrimental effects depending on context.
Immune Modulation
Exosomes are key mediators of immune cell crosstalk. Cancer-derived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B. Exosomal PD-1 from prostate cancer cells enhances MDSC activity, promoting immune evasion. Exosomal circCCAR1 impairs CD8+ T-cell function, contributing to anti-PD1 resistance. These examples highlight how positive regulation of exosomal secretion can shape the immune microenvironment in disease.
From positive regulation of exosomal secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X promote exosome secretion? | CRISPR knockout of gene X in cells, followed by exosome quantification (NTA, CD63 ELISA) |
| Does a point mutation in gene X affect exosome secretion? | CRISPR knock-in of specific point mutation, compare to wild-type [general approach] |
| Does overexpression of gene X increase exosome release? | CRISPR activation (CRISPRa) or lentiviral overexpression, measure exosome production |
| What is the role of a specific exosomal cargo? | Knock-in of tagged cargo protein (e.g., GFP-CD63) for tracking [general approach] |
| Can we identify novel regulators of exosomal secretion? | Genome-wide CRISPR knockout library screening with exosome reporter [general approach] |
| Does gene X regulate exosome secretion in vivo? | Conditional knockout mouse models (e.g., myeloid-specific IL-6 KO) |
How to Study the positive regulation of exosomal secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Nanoparticle Tracking Analysis (NTA) | Concentration and size distribution of exosomes | Quantify exosome secretion after genetic manipulation [1,5] |
| Transmission Electron Microscopy (TEM) | Morphology of exosomes | Confirm exosome identity and purity |
| Western Blot | Expression of exosome markers (CD63, CD81, TSG101) | Validate exosome isolation and quantify secretion |
| CRISPR Knockout Screening | Identification of genes affecting exosome secretion | Discover novel positive regulators [general approach] |
| RNA Sequencing | Transcriptomic changes in cells and exosomal cargo | Elucidate signaling pathways and cargo sorting [3,4] |
| Proteomics | Protein composition of exosomes | Identify cargo and post-translational modifications |
| Flow Cytometry | Surface markers on exosomes or recipient cells | Assess immune cell polarization [1,4] |
| Luciferase Reporter Assay | Activity of signaling pathways (e.g., NF-kB, STAT3) | Measure pathway activation by positive regulators [2,6] |
Exosome Isolation and Characterization
Standard methods include differential ultracentrifugation, size-exclusion chromatography, and polymer-based precipitation. Characterization by nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and Western blot for markers (CD63, CD81, TSG101) is essential. These methods are used to quantify exosome secretion in response to positive regulators [1,2,5].
CRISPR Screening for Regulators
Genome-wide CRISPR knockout or activation screens can identify genes that positively regulate exosomal secretion. Cells are engineered to express a reporter (e.g., luciferase-tagged CD63), and exosome release is measured. Hits are validated individually. This approach is powerful for discovering novel regulators [general approach].
RNA Sequencing and Proteomics
RNA-seq of cells and exosomal cargo can reveal changes in gene expression and cargo sorting upon positive regulation. Proteomics of exosomes identifies cargo proteins and post-translational modifications. These methods help elucidate mechanisms downstream of regulatory signals [3,4,8].
Functional Assays in Recipient Cells
To assess the biological effects of increased exosomal secretion, exosomes are added to recipient cells, and functional readouts such as macrophage polarization, T-cell activation, or fibrosis markers are measured. For example, exosomal miR-934 induces M2 polarization in macrophages, and exosomal PD-1 enhances MDSC activity.
How CRISPR Can Be Used to Study GO:1903543 positive regulation of exosomal secretion
Knockout
CRISPR knockout is used to delete genes suspected to positively regulate exosomal secretion. For example, knocking out GP73 in colorectal cancer cells reduces exosome biogenesis and liver metastasis. Knockout of IL-6 signaling components in myeloid cells decreases exosome production. These models help establish causality.
Point Mutation
CRISPR point mutation introduces specific amino acid changes to dissect functional domains. For instance, mutating phosphorylation sites in a regulator can determine if phosphorylation is required for enhanced exosome secretion. This approach is useful for studying signaling events [general approach].
Knock-in
CRISPR knock-in can tag endogenous proteins with fluorescent markers (e.g., GFP-CD63) to track exosome secretion in real time. It can also introduce disease-associated mutations to study their effect on exosome release. This provides precise models for dynamic studies [general approach].
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression is used to increase expression of candidate positive regulators. For example, overexpressing TNF-alpha or IL-6 in cells enhances exosome secretion [2,6]. Overexpression models help confirm sufficiency of a gene in promoting exosomal secretion.
How EDITGENE Supports positive regulation of exosomal secretion Research
Researchers studying positive regulation of exosomal secretion-related genes often need to determine whether a candidate gene is causally involved in exosome biogenesis, trafficking, or release. This requires precise genetic manipulation and functional validation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such studies, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of exosomal secretion research.
Frequently Asked Questions About positive regulation of exosomal secretion
What is GO:1903543?
GO:1903543 is a Gene Ontology term for positive regulation of exosomal secretion, describing any process that increases the frequency, rate, or extent of exosome release from cells.
What genes are involved in positive regulation of exosomal secretion?
Key genes include miR-934, TNF-alpha, circCCAR1, miR-138-5p, GP73, IL-6, LCN2, and PD-1, as shown in recent studies [1,2,3,4,5,6,7,8].
How is exosomal secretion positively regulated?
It is regulated by signaling pathways such as TNF-alpha/NF-kB and IL-6/STAT3, which enhance exosome biogenesis, cargo sorting, MVB trafficking, and membrane fusion [2,6].
What diseases are associated with increased exosomal secretion?
Increased exosomal secretion is linked to cancer metastasis, immune evasion, fibrosis, and intervertebral disc degeneration [1,3,5,6,7,8].
What methods are used to study positive regulation of exosomal secretion?
Common methods include nanoparticle tracking analysis, Western blot for exosome markers, CRISPR screening, RNA-seq, and functional assays in recipient cells [1,5].
Can CRISPR be used to study exosomal secretion?
Yes, CRISPR knockout, knock-in, and activation are powerful tools to manipulate genes and assess their effects on exosome release [5,6].
What is the role of GP73 in exosomal secretion?
GP73 regulates exosome biogenesis and promotes colorectal cancer liver metastasis, making it a potential therapeutic target.
How does IL-6 affect exosomal secretion?
IL-6 signaling in myeloid cells increases production of miR-223-enriched exosomes, which attenuates NAFLD-associated fibrosis.
What is the significance of exosomal PD-1?
Prostate cancer cells secrete PD-1 in exosomes to enhance myeloid-derived suppressor cell activity, promoting immune evasion.
What are the challenges in studying exosomal secretion?
Challenges include isolating pure exosomes, distinguishing subtypes, and linking specific cargo to functional outcomes. CRISPR models and advanced imaging help overcome these.
Conclusion
Positive regulation of exosomal secretion (GO:1903543) is a dynamic and clinically relevant biological process. It governs the release of exosomes that mediate intercellular communication in cancer, immunity, and metabolism. Key regulators such as miR-934, GP73, IL-6, and PD-1 have been experimentally linked to disease progression and therapeutic resistance [1,5,6,8]. Understanding the molecular mechanisms and identifying novel regulators through CRISPR-based approaches will pave the way for new diagnostics and treatments. EDITGENE provides the tools and expertise to accelerate this research.
References
- 1. Zhao S et al.. 2020. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer.. J Hematol Oncol 13(1):156 PMID: 33213490
- 2. Nakao Y et al.. 2021. Exosomes from TNF-α-treated human gingiva-derived MSCs enhance M2 macrophage polarization and inhibit periodontal bone loss.. Acta Biomater 122:306-324 PMID: 33359765
- 3. Hu Z et al.. 2023. Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma.. Mol Cancer 22(1):55 PMID: 36932387
- 4. Xun J et al.. 2021. Cancer-derived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B.. Theranostics 11(14):6847-6859 PMID: 34093857
- 5. Huang L et al.. 2025. GP73-dependent regulation of exosome biogenesis promotes colorectal cancer liver metastasis.. Mol Cancer 24(1):151 PMID: 40414849
- 6. Hou X et al.. 2021. Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.. Hepatology 74(1):116-132 PMID: 33236445
- 7. Fan C et al.. 2024. M1 macrophage-derived exosomes promote intervertebral disc degeneration by enhancing nucleus pulposus cell senescence through LCN2/NF-κB signaling axis.. J Nanobiotechnology 22(1):301 PMID: 38816771
- 8. Zhang J et al.. 2025. Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion.. Cancer Res 85(18):3435-3453 PMID: 40698651
